Research programme: neurodegenerative disorders/pain therapeutics - Mimetogen Pharmaceuticals

Drug Profile

Research programme: neurodegenerative disorders/pain therapeutics - Mimetogen Pharmaceuticals

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mimetogen Pharmaceuticals
  • Class Nerve growth factors; Small molecules
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Neurodegenerative disorders; Pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Neurodegenerative-disorders in Canada
  • 16 Jul 2016 No recent reports of development identified for research development in Pain in Canada
  • 19 Oct 2009 Neurodegenerative disorders/pain therapeutics - Mimetogen Pharmaceuticals available for licensing in Canada (http://www.mimetogen.com/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top